Transaction with special purpose acquisition company totals $138 million.
Celularity Inc., a clinical-stage cellular medicine company developing off-the-shelf allogeneictherapies derived from the postpartum human placenta, announced the closing of a merger with GX Acquisition Corp., a special purpose acquisition company (SPAC). Proceeds from the transaction totaled approximately $138 million. The combined, publicly traded company will operate under the name Celularity, Inc., and its common stock will commence trading on the Nasdaq Capital Market on July 19, 2021, under the ticker symbol “CELU.”
Celularity’s Founder, Chairperson and CEO, Robert J. Hariri, MD, PhD, has decades of R&D experience. The company’s pipeline is centered on its biologic CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy. CYNK-001 is currently in a Phase I trial for patients with acute myeloid leukemia (AML) and has been granted Orphan Drug Designation by the FDA for the treatment of patients with malignant gliomas. In addition, CYNK-001 received a positive recommendation from an independent Data Monitoring Committee to continue advancing the company’s Phase I/II COVID-19 trial.
Read more about the merger here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.